Breast Cancer Clinical Trials in Michigan

Showing 61-80 of 276 trials

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

NCT01766297

The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.

Breast CancerBreast NeoplasmBreast Tumor+1 more

Proton Collaborative Group132 participantsStarted Feb 2013

Scottsdale, Arizona, United States • San Diego, California, United States • Warrenville, Illinois, United States +6 more locations

COMPLETEDPHASE362 miles

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.

Breast Carcinoma

University of Rochester NCORP Research Base1,363 participantsStarted Apr 2018

Honolulu, Hawaii, United States • Decatur, Illinois, United States • New Orleans, Louisiana, United States +15 more locations

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Breast Cancer Trials in Other Cities

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study of XMT-1660 in Participants With Solid Tumors

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

MARGetuximab Or Trastuzumab (MARGOT)

Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Other Conditions in Michigan